1 Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models[J]. Lancet Neurol, 2019, 18(11): 1045-1057. PMID: 31326280. DOI: 10.1016/S1474-4422(19)30244-3.
2 Li X, Hou C, Wu WL, et al. Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: analysis of 111 cases[J]. J Neuroimmunol, 2021, 352: 577479. PMID: 33486307. DOI: 10.1016/j.jneuroim.2021.577479.
3 Xu X, Lu Q, Huang Y, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(1): e633. PMID: 31619447. PMCID: PMC6857906. DOI: 10.1212/NXI.0000000000000633.
4 Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function[J]. Pharmacol Rev, 2010, 62(3): 405-496. PMID: 20716669. PMCID: PMC2964903. DOI: 10.1124/pr.109.002451.
5 Bost C, Chanson E, Picard G, et al. Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies[J]. J Neurol, 2018, 265(10): 2190-2200. PMID: 30003358. DOI: 10.1007/s00415-018-8970-0.
6 Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis[J]. Lancet Neurol, 2018, 17(9): 760-772. PMID: 30049614. PMCID: PMC6128696. DOI: 10.1016/S1474-4422(18)30244-8.
7 Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias lecture[J]. Neurology, 2016, 87(23): 2471-2482. PMID: 27920282. PMCID: PMC5177671. DOI: 10.1212/WNL.0000000000003414.
8 Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis[J]. J Neurosci, 2010, 30(17): 5866-5875. PMID: 20427647. PMCID: PMC2868315. DOI: 10.1523/JNEUROSCI.0167-10.2010.
9 Zrzavy T, Endmayr V, Bauer J, et al. Neuropathological variability within a spectrum of NMDAR-encephalitis[J]. Ann Neurol, 2021, 90(5): 725-737. PMID: 34562035. DOI: 10.1002/ana.26223.
10 Wagnon I, Hélie P, Bardou I, et al. Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor[J]. Brain, 2020, 143(10): 2957-2972. PMID: 32893288. DOI: 10.1093/brain/awaa250.
11 Chetaille Nézondet AL, Poubelle PE, Pelletier M. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases[J]. J Leukoc Biol, 2020, 108(2): 647-657. PMID: 32040246. DOI: 10.1002/JLB.5MR0120-218RRR.
12 Pan Z, Zhu T, Liu Y, et al. Role of the CXCL13/CXCR5 axis in autoimmune diseases[J]. Front Immunol, 2022, 13: 850998. PMID: 35309354. PMCID: PMC8931035. DOI: 10.3389/fimmu.2022.850998.
13 Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease[J]. Cold Spring Harb Perspect Biol, 2014, 6(10): a016295. PMID: 25190079. PMCID: PMC4176007. DOI: 10.1101/cshperspect.a016295.
14 Alawdi SH, El-Denshary ES, Safar MM, et al. Neuroprotective effect of nanodiamond in Alzheimer's disease rat model: a pivotal role for modulating NF-κB and STAT3 signaling[J]. Mol Neurobiol, 2017, 54(3): 1906-1918. PMID: 26897372. DOI: 10.1007/s12035-016-9762-0.
15 Haramati A, Rechtman A, Zveik O, et al. IL-6 as a marker for NMOSD disease activity[J]. J Neuroimmunol, 2022, 370: 577925. PMID: 35810527. DOI: 10.1016/j.jneuroim.2022.577925.
16 Li Q, Chen J, Yin M, et al. High level of soluble CD146 in cerebrospinal fluid might be a biomarker of severity of anti-N-methyl-D-Aspartate receptor encephalitis[J]. Front Immunol, 2021, 12: 680424. PMID: 34220828. PMCID: PMC8245058. DOI: 10.3389/fimmu.2021.680424.
17 Liu J, Liu L, Kang W, et al. Cytokines/chemokines: potential biomarkers for non-paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis[J]. Front Neurol, 2020, 11: 582296. PMID: 33408682. PMCID: PMC7779630. DOI: 10.3389/fneur.2020.582296.
18 Wang X, Ma C, Liu CY, et al. Neuronal NMDAR currents of the hippocampus and learning performance in autoimmune anti-NMDAR encephalitis and involvement of TNF-α and IL-6[J]. Front Neurol, 2019, 10: 684. PMID: 31297084. PMCID: PMC6607466. DOI: 10.3389/fneur.2019.00684.
19 Lee WJ, Lee ST, Shin YW, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis[J]. Neurotherapeutics, 2021, 18(1): 474-487. PMID: 32880854. PMCID: PMC8116457. DOI: 10.1007/s13311-020-00921-7.
20 Veldhoen M. Interleukin 17 is a chief orchestrator of immunity[J]. Nat Immunol, 2017, 18(6): 612-621. PMID: 28518156. DOI: 10.1038/ni.3742.
21 Regen T, Isaac S, Amorim A, et al. IL-17 controls central nervous system autoimmunity through the intestinal microbiome[J]. Sci Immunol, 2021, 6(56): eaaz6563. PMID: 33547052. DOI: 10.1126/sciimmunol.aaz6563.
22 Zeng C, Chen L, Chen B, et al. Th17 cells were recruited and accumulated in the cerebrospinal fluid and correlated with the poor prognosis of anti-NMDAR encephalitis[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(12): 1266-1273. PMID: 30418472. DOI: 10.1093/abbs/gmy137.
23 Peng Y, Liu B, Pei S, et al. Higher CSF levels of NLRP3 inflammasome is associated with poor prognosis of anti-N-methyl-D-aspartate receptor encephalitis[J]. Front Immunol, 2019, 10: 905. PMID: 31214158. PMCID: PMC6554706. DOI: 10.3389/fimmu.2019.00905.
24 Balasa R, Bianca C, Septimiu V, et al. The matrix metalloproteinases panel in multiple sclerosis patients treated with natalizumab: a possible answer to natalizumab non- responders[J]. CNS Neurol Disord Drug Targets, 2018, 17(6): 464-472. PMID: 29968546. DOI: 10.2174/1871527317666180703102536.
25 Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in Plaque Psoriasis[J]. N Engl J Med, 2021, 385(2): 142-152. PMID: 33891380. DOI: 10.1056/NEJMoa2102383.
26 Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response[J]. Curr Opin Pharmacol, 2006, 6(4): 379-386. PMID: 16713356. DOI: 10.1016/j.coph.2006.01.010.
27 Mege JL, Meghari S, Honstettre A, et al. The two faces of interleukin 10 in human infectious diseases[J]. Lancet Infect Dis, 2006, 6(9): 557-569. PMID: 16931407. DOI: 10.1016/S1473-3099(06)70577-1.
28 Xin G, Zander R, Schauder DM, et al. Single-cell RNA sequencing unveils an IL-10-producing helper subset that sustains humoral immunity during persistent infection[J]. Nat Commun, 2018, 9(1): 5037. PMID: 30487586. PMCID: PMC6261948. DOI: 10.1038/s41467-018-07492-4.
29 Qiao J, Liu Z, Dong C, et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis[J]. Cancer Cell, 2019, 35(6): 901-915.e4. PMID: 31185213. DOI: 10.1016/j.ccell.2019.05.005.
30 Yogev N, Bedke T, Kobayashi Y, et al. CD4+ T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival[J]. Cell Rep, 2022, 38(13): 110565. PMID: 35354043. DOI: 10.1016/j.celrep.2022.110565.
31 Peng Y, Zheng D, Zhang X, et al. Cell-Free mitochondrial DNA in the CSF: a potential prognostic biomarker of anti-NMDAR encephalitis[J]. Front Immunol, 2019, 10: 103. PMID: 30792710. PMCID: PMC6375341. DOI: 10.3389/fimmu.2019.00103.
32 Sáez de Guinoa J, Barrio L, Mellado M, et al. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics[J]. Blood, 2011, 118(6): 1560-1569. PMID: 21659539. DOI: 10.1182/blood-2011-01-332106.
33 Harrer C, Otto F, Pilz G, et al. The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF[J]. Fluids Barriers CNS, 2021, 18(1): 40. PMID: 34446066. PMCID: PMC8390062. DOI: 10.1186/s12987-021-00272-1.
34 Eckman EA, Clausen DM, Herdt AR, et al. Specificity and diagnostic utility of cerebrospinal fluid CXCL13 in Lyme neuroborreliosis[J]. Clin Infect Dis, 2021, 72(10): 1719-1726. PMID: 32221538. DOI: 10.1093/cid/ciaa335.
35 Barstad B, Henningsson AJ, Tveitnes D, et al. Cerebrospinal fluid cytokines and chemokines in children with Lyme neuroborreliosis; pattern and diagnostic utility[J]. Cytokine, 2020, 130: 155023. PMID: 32199247. DOI: 10.1016/j.cyto.2020.155023.
36 Lucchini M, De Arcangelis V, Piro G, et al. CSF CXCL13 and chitinase 3-like-1 levels predict disease course in relapsing multiple sclerosis[J]. Mol Neurobiol, 2023, 60(1): 36-50. PMID: 36215027. PMCID: PMC9758105. DOI: 10.1007/s12035-022-03060-6.
37 Li Y, Yang K, Zhang F, et al. Identification of cerebrospinal fluid biomarker candidates for anti-N-methyl-D-aspartate receptor encephalitis: high-throughput proteomic investigation[J]. Front Immunol, 2022, 13: 971659. PMID: 36389787. PMCID: PMC9643472. DOI: 10.3389/fimmu.2022.971659.
38 Leypoldt F, H?ftberger R, Titulaer MJ, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response[J]. JAMA Neurol, 2015, 72(2): 180-186. PMID: 25436993. PMCID: PMC4836910. DOI: 10.1001/jamaneurol.2014.2956.
39 Kothur K, Wienholt L, Mohammad SS, et al. Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis[J]. PLoS One, 2016, 11(8): e0161656. PMID: 27575749. PMCID: PMC5004915. DOI: 10.1371/journal.pone.0161656.
40 Liu B, Liu J, Sun H, et al. Autoimmune encephalitis after Japanese encephalitis in children: a prospective study[J]. J Neurol Sci, 2021, 424: 117394. PMID: 33773410. DOI: 10.1016/j.jns.2021.117394.
41 Pilz G, Sakic I, Wipfler P, et al. Chemokine CXCL13 in serum, CSF and blood—CSF barrier function: evidence of compartment restriction[J]. Fluids Barriers CNS, 2020, 17(1): 7. PMID: 32089130. PMCID: PMC7038591. DOI: 10.1186/s12987-020-0170-5.
42 Dai S, Liu F, Qin Z, et al. Kupffer cells promote T-cell hepatitis by producing CXCL10 and limiting liver sinusoidal endothelial cell permeability[J]. Theranostics, 2020, 10(16): 7163-7177. PMID: 32641985. PMCID: PMC7330839. DOI: 10.7150/thno.44960.
43 Nohejlova H, Kayserova J, Capek V, et al. Paediatric onset of multiple sclerosis: analysis of chemokine and cytokine levels in the context of the early clinical course[J]. Mult Scler Relat Disord, 2020, 46: 102467. PMID: 32889374. DOI: 10.1016/j.msard.2020.102467.
44 吕遐, 徐晓璐, 任海涛, 等. 抗N-甲基-D-天冬氨酸受体脑炎患者细胞因子检测及其临床意义[J]. 中国神经免疫学和神经病学杂志, 2021, 28(3): 214-218, 223. DOI: 10.3969/j.issn.1006-2963.2021.03.009.
45 Shaul ME, Zlotnik A, Tidhar E, et al. Tumor-associated neutrophils drive B-cell recruitment and their differentiation to plasma cells[J]. Cancer Immunol Res, 2021, 9(7): 811-824. PMID: 33906865. DOI: 10.1158/2326-6066.CIR-20-0839.
46 Smulski CR, Zhang L, Burek M, et al. Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells[J]. Cell Rep, 2022, 38(13): 110583. PMID: 35354034. DOI: 10.1016/j.celrep.2022.110583.
47 Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity[J]. Cytokine Growth Factor Rev, 2013, 24(3): 203-215. PMID: 23684423. PMCID: PMC7108297. DOI: 10.1016/j.cytogfr.2013.04.003.
48 Baert L, Benkhoucha M, Popa N, et al. A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosis[J]. Ann Neurol, 2019, 85(3): 406-420. PMID: 30635946. DOI: 10.1002/ana.25415.
49 Lim KH, Chen LC, Hsu K, et al. BAFF-driven NLRP3 inflammasome activation in B cells[J]. Cell Death Dis, 2020, 11(9): 820. PMID: 33004801. PMCID: PMC7529748. DOI: 10.1038/s41419-020-03035-2.
50 Deng B, Liu XN, Li X, et al. Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: correlation with clinical outcome[J]. J Neuroimmunol, 2017, 305: 84-91. PMID: 28284352. DOI: 10.1016/j.jneuroim.2017.01.012.
51 Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128. PMID: 32937045. DOI: 10.1056/NEJMoa2001180.